To test the effect of mTORC1 inhibition on RON-driven metastatic breast cancer, we established a model wherein T47D-RON cells were injected into the tail vein of NSG mice and then, upon clear detection of metastatic lesions by in vivo IVIS imaging, randomized to receive either an FDA-approved mTORC1 inhibitor, everolimus, or vehicle control treatment (see Fig. 6a for the experimental scheme, and Supplementary Figure S15 for tissue tropism of metastasis following injection of T47D-RON cells). This evidence concerns the gene MST1R and breast carcinoma.